Abstract:The CRISPR(clustered regularly interspersed short palindromic repeats)/Cas9 system has emerged as a transforming genome editing tool. Cas9/sgRNA recognizes the protospacer-adjacent motif (PAM) sequence and a complementary 20 nucleotide genomic sequence and induces double stranded DNA breaks (DSBs), which are repaired by error-prone non-homologous end-joining (NHEJ) or precise homology-directed repair (HDR). CRISPR/Cas9 genome editing has been applied to correct disease-causing mutations in mouse zygotes and human cell lines, but delivery to adult mammalian organs to correct genetic disease genes has not been reported prior to our study. The liver disease hereditary tyrosinemia type I is a particularly suitable model for gene repair-based therapy because the repaired hepatocytes will expand and repopulate the liver. In tyrosinemia patients, mutation of fumarylacetoacetate hydrolase (FAH), the last enzyme catalyzing the tyrosine catabolic pathway, leads to accumulation of toxic metabolites and severe liver damage. The Fahmut/mut mouse model is caused by a G->A point mutation in the last nucleotide of exon 8. This causes splicing skipping of exon 8 and truncated Fah messenger RNA (mRNA). These mice can be treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), an inhibitor of an enzyme upstream of FAH, to prevent toxin accumulation in hepatocytes. In our first proof-of-concept study, we demonstrate CRISPR/Cas9-mediated correction of a Fah mutation in hepatocytes in a mouse model of the human disease hereditary tyrosinemia. Delivery of components of the CRISPR/Cas9 system by hydrodynamic injection resulted in initial expression of the wild-type Fah protein in ~1/250 liver cells. Expansion of Fah-positive hepatocytes rescued the body weight loss phenotype. Our study indicates that for the first time CRISPR/Cas9-mediated genome editing is possible in adult animals and has potential for correction of human genetic diseases. The combination of Cas9, guide RNA and repair template DNA can induce precise gene editing and the correction of genetic diseases in adult mammals. However, clinical implementation of this technology requires safe and effective delivery of all of these components into the nuclei of the target tissue. Here in our second study, we combined lipid nanoparticle—mediated delivery of Cas9 mRNA with adeno-associated viruses encoding a sgRNA and a repair template to induce repair of a disease gene in adult animals. We applied our delivery strategy to a mouse model of human hereditary tyrosinemia and show that the treatment generated Fah-positive hepatocytes by correcting the causative Fah splicing mutation. Treatment rescued disease symptoms such as weight loss and liver damage. The efficiency of correction was >6% of hepatocytes after a single application, suggesting potential utility of Cas9-based therapeutic genome editing for a range of diseases.

Efficient expansion and CRISPR-Cas9-mediated gene correction of patient-derived hepatocytes for treatment of inherited liver diseases

487. Therapeutic Genome Editing by Combined Viral and Non-Viral Delivery of CRISPR System Components to the Mouse Liver

Therapeutic liver cell transplantation to treat a genetic liver defect

Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1

Efficient Drug Screening and Gene Correction for Treating Liver Disease Using Patient-Specific Stem Cells

Therapeutic Cell Repopulation of the Liver: From Fetal Rat Cells to Synthetic Human Tissues

Gene Editing Correction of a Urea Cycle Defect in Organoid Stem Cell Derived Hepatocyte-like Cells

Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases

Direct Reprogramming of Human Fibroblasts to Functional and Expandable Hepatocytes.

Potential treatment of liver-related disorders with in vitro expanded human liver precursors.

Could co-transplantation of iPS cells derived hepatocytes and MSCs cure end-stage liver disease?

Therapeutic liver cell transplantation to treat murine PKU

Direct reprogramming of fibroblasts into functional hepatocytes via CRISPRa activation of endogenous Gata4 and Foxa3

Establishment Of Highly Differentiated Immortalized Human Hepatocyte Line With Simian Virus 40 Large Tumor Antigen For Liver Based Cell Therapy

CRISPR-targeted genome editing of human induced pluripotent stem cell-derived hepatocytes for the treatment of Wilson’s disease

Gene editing technology as an approach to the treatment of liver diseases

Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases

Genetic Modification of Hepatocytes towards Hepatocyte Transplantation and Liver Tissue Engineering

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I

Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion